Second Alzheimer's slowing drug to seek approval in the US

euronews (in English)
euronews (in English)
  • 11 months ago
Donanemab has proven to slow disease progression by several months in some patients but has also shown serious side effects.
0:32
I
Up next
Leukemia Medication Shows Promise In Slowing Alzheimer's Disease
Life For Tips
0:32
Leukemia Medication Shows Promise In Slowing Alzheimer's Disease
Wochit
1:14
Chris Hemsworth thinking of ‘slowing down’ learning he’s at 'high risk' of Alzheimer’s
Bang Premier
8:49
Joe Biden Forgets Where He Is Again Due to His Alzheimers Disease
Styxhexenhammer666
0:54
Having gum disease increases chances of developing alzheimers
BANGShowbiz-Bizarre
1:33
New Alzheimer's treatment: Donanemab drug seen as turning point in fight against disease
FRANCE 24 English
1:44
Le Donanemab, nouveau traitement prometteur qui ralentit la progression d'Alzheimer
Aufeminin
1:00
French rains drench bees and their habitats
euronews (in English)
7:00
State of the Union: EU top jobs and Nature Restoration law
euronews (in English)
1:00
WATCH: "unprecedented" floods hit Craon in western France
euronews (in English)
5:00
Baku Energy Forum focuses on AI, economic growth, and clean energy transition
euronews (in English)
3:00
Gamesummit 2024 sees thrilling competitions, shows, and insightful discussions about gaming
euronews (in English)
2:37
Les Bleus unite a divided France ahead of elections
euronews (in English)
0:54
US recovers with win over Brazil in Men's VNL
The Manila Times
1:48
'Suffocating heat': Body of US-bound migrant recovered at Mexico border
AFP English
0:34
U.S. includes Japan to its currency watchlist
PTVPhilippines
22:23
How AI can combat burnout among America's healthcare workers
Fortune
4:58
Dem Lawmakers Asked Point Blank About Biden Executive Order Limiting Asylum Seekers Entry To The US
Forbes Breaking News
3:08
Veronica Escobar Thanks Biden For New Executive Order To Help Undocumented Spouses Of U.S. Citizens
Forbes Breaking News

Featured channels

More from
Met Office
More from
ODN
More from
SWNS
More from
GoodtoKnow
More from
Evening Standard
More from
FourFourTwo